Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall su...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4911051?pdf=render |
| _version_ | 1819067632463118336 |
|---|---|
| author | Brian D Lehmann Bojana Jovanović Xi Chen Monica V Estrada Kimberly N Johnson Yu Shyr Harold L Moses Melinda E Sanders Jennifer A Pietenpol |
| author_facet | Brian D Lehmann Bojana Jovanović Xi Chen Monica V Estrada Kimberly N Johnson Yu Shyr Harold L Moses Melinda E Sanders Jennifer A Pietenpol |
| author_sort | Brian D Lehmann |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival. Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients. Previously, we developed an approach to identify six molecular subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to standard-of-care chemotherapy. Given the complexity of the varying histological landscape of tumor specimens, we used histopathological quantification and laser-capture microdissection to determine that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-associated stromal cells, respectively. Therefore, we refined TNBC molecular subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathology. Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches. Combined analysis of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathological complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], respectively). Collectively, we provide pre-clinical data that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes. |
| first_indexed | 2024-12-21T16:21:20Z |
| format | Article |
| id | doaj.art-97ca7f5bafa5463aa0f35937384d1455 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T16:21:20Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-97ca7f5bafa5463aa0f35937384d14552022-12-21T18:57:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015736810.1371/journal.pone.0157368Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.Brian D LehmannBojana JovanovićXi ChenMonica V EstradaKimberly N JohnsonYu ShyrHarold L MosesMelinda E SandersJennifer A PietenpolTriple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival. Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients. Previously, we developed an approach to identify six molecular subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to standard-of-care chemotherapy. Given the complexity of the varying histological landscape of tumor specimens, we used histopathological quantification and laser-capture microdissection to determine that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-associated stromal cells, respectively. Therefore, we refined TNBC molecular subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathology. Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches. Combined analysis of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathological complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], respectively). Collectively, we provide pre-clinical data that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes.http://europepmc.org/articles/PMC4911051?pdf=render |
| spellingShingle | Brian D Lehmann Bojana Jovanović Xi Chen Monica V Estrada Kimberly N Johnson Yu Shyr Harold L Moses Melinda E Sanders Jennifer A Pietenpol Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE |
| title | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. |
| title_full | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. |
| title_fullStr | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. |
| title_full_unstemmed | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. |
| title_short | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. |
| title_sort | refinement of triple negative breast cancer molecular subtypes implications for neoadjuvant chemotherapy selection |
| url | http://europepmc.org/articles/PMC4911051?pdf=render |
| work_keys_str_mv | AT briandlehmann refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT bojanajovanovic refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT xichen refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT monicavestrada refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT kimberlynjohnson refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT yushyr refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT haroldlmoses refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT melindaesanders refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection AT jenniferapietenpol refinementoftriplenegativebreastcancermolecularsubtypesimplicationsforneoadjuvantchemotherapyselection |